Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Completed 10Terminated 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2Genitourinary 2Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Melanoma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × CB-839 × Clear all
NCT03944902 2023-11-21

BRCA

University of Alabama at Birmingham

Phase 1 Terminated
1 enrolled
Gynecologic

Ovarian Neoplasms

NCT02771626 2023-03-17

Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)

Calithera Biosciences, Inc

Phase 1/2 Terminated
118 enrolled 18 charts
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04265534 2022-09-21

KEAPSAKE

Calithera Biosciences, Inc

Phase 2 Terminated
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03875313 2022-02-17

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Calithera Biosciences, Inc

Phase 1/2 Terminated
33 enrolled 14 charts
BreastGastrointestinalGenitourinary

Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡